Showing 3531-3540 of 5693 results for "".
- New Research Highlights Lumenis Dynamic Muscle Stimulation Technology in Managing Lower Lid Laxity and Blinking Qualityhttps://modernod.com/news/new-research-highlights-lumenis-dynamic-muscle-stimulation-technology-in-managing-lower-lid-laxity-and-blinking-quality/2482929/New findings demonstrating Lumenis’s Dynamic Muscle Stimulation technology (DMSt) can effectively address lower lid laxity and improve blinking quality in patients with dry eye disease (DED).[1]. According to Lumenis,
- Mark Maire Appointed CEO of Rebionhttps://modernod.com/news/mark-maire-appointed-ceo-of-rebion/2482920/Rebion, a provider of neuro-visual diagnostics and digital retinal imaging technologies, announced the appointment of Mark Maire as Chief Executive Officer. Mr. Maire brings more than two decades of commercial leadership and strategic growth experience, including the sale of TrueVi
- Market Scope: Investor Interest in Ophthalmology Remains Stronghttps://modernod.com/news/market-scope-investor-interest-in-ophthalmology-remains-strong/2482919/The ophthalmic industry continues to command the attention of investors with $620 million raised across 13 transactions in Q2 2025, according to Market Scope’s latest Ophthalmic Deals Report. However, the investment dollars are down from Q2-2024 and
- Alcon to Acquire Staar Surgical for $1.5 Billionhttps://modernod.com/news/alcon-to-acquire-staar-surgical-for-15-billion/2482917/In a major deal to expand its refractive portfolio and continue its spree of acquisitions, Alcon has agreed to acquire Staar Surgical, maker of the Implantable Collamer Lens (ICL). The acquisition includes the EVO family of l
- Genentech Unveils 5-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatmenthttps://modernod.com/news/genentech-unveils-five-year-data-for-susvimo-long-term-efficacy-and-durability-in-wet-amd-treatment/2482915/Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The fin
- Topcon Healthcare Acquires Intelligent Retinal Imaging Systemshttps://modernod.com/news/topcon-healthcare-acquires-intelligent-retinal-imaging-systems-to-enhance-connected-care-across-primary-and-eye-care/2482909/Topcon Healthcare announced the acquisition of Intelligent Retinal Imaging Systems (IRIS), a US-based provider of cloud-based retinal screening technology. FInancial terms of the deal were not disclosed. IRIS bri
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- Ziemer USA Announces New Innovations for the Galilei Diagnostic Platform and FEMTO LDV Z8 Femtosecond Laserhttps://modernod.com/news/ziemer-usa-announces-new-innovations-for-the-galilei-diagnostic-platform-and-femto-ldv-z8-femtosecond-laser-platform/2482904/Ziemer USA, in partnership with CorneaGen, announced the launch of the Galilei CTAK module, which is now available for use with the Galilei diagnostic platform. "We are thrilled to complete our product offering for CTAK patients. With the addition of the Galilei CTAK module in combination
- Alcon Showcases Surgical Efficiency of Unity VCS Innovations at ASRS 2025https://modernod.com/news/alcon-showcases-surgical-efficiency-of-unity-vcs-innovations-at-asrs-2025/2482903/Alcon will showcase its latest clinical data and innovations at the 2025 American Society of Retina Specialists (ASRS) annual meeting, July 31 to August 2, in Long Beach, California. Attendees can explore Alcon’s latest surgical advancements through scientific presentations and hands-on dem
- Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindnesshttps://modernod.com/news/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapy-for-inherited-childhood-blindness/2482902/Opus Genetics announced a partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. The Alliance serves as a collaborative platform uniting advocacy groups dedicated to RDH